Oncology | Tracking rapid innovation in cancer care

Oncology

ESMO25: Perspective on ‘inside-out oncology’ and targeted al...

Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.

News

Enhertu moves into frontline breast cancer treatment

Daiichi Sankyo and AstraZeneca's Enhertu has become the first new first-line option in the US for HER2-positive breast cancer in more than a decade.

News

J&J claims FDA's latest national priority voucher

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.

Oncology

pharmaphorum podcast Episode 229, Craig Eagle, Guardant Health

How blood tests can inform cancer treatment decisions, with ...

Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.

News

SanegeneBio raises $110m for RNAi, plus other financings

Biotech financings this week include SanegeneBio's Lilly-backed $110m Series B, with Sidera, D3 Bio, BlossomHill, and Prolynx also raising new funds.

News

Doctor speaks with patient in his consultation room

Limited prostate cancer screening backed in UK

A recommendation on prostate cancer screening has been delivered in the UK, upsetting patient groups whilst being endorsed by medical organisations.

News

Veraxa says delayed US listing is back on track

Swiss biotech Veraxa's listing on the Nasdaq, delayed by the record 43-day US government shutdown, should now complete in the first quarter of 2026.

Oncology

Targeting blood cancers with high unmet need

When it comes to myeloid malignancies such as acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), treatment progress has been slow.

News

Enhertu moves into frontline breast cancer treatment

Daiichi Sankyo and AstraZeneca's Enhertu has become the first new first-line option in the US for HER2-positive breast cancer in more than a decade.

News

J&J claims FDA's latest national priority voucher

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.

Views & Analysis

Oncology

ESMO25: Perspective on ‘inside-out oncology’ and targeted al...

Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.

Oncology

How blood tests can inform cancer treatment decisions, with ...

Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.

Deep Dive

Oncology

City Cancer Challenge: A gender-focused revolution in global...

Oncology

Cell and gene therapies: Stagnation or maturation?

Webinars

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Oncology

Sponsored

How can digital and AI optimise the delivery of patient supp...

How can digital and AI optimise the delivery of patient support programs in cancer?

Oncology

Sponsored

Clinical decision-making insights for haem/oncs

Despite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several decision-making challenges for healthcare professionals.

Oncology

IQVIA_webinar_holding_slide-07.04.20-1200x675-NEW

Sponsored

Unlocking health data to improve oncology outcomes

The NHS’ globally unique health data ecosystem has the potential to improve health outcomes.

Podcasts

Oncology

How blood tests can inform cancer treatment decisions, with ...

Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.

Oncology

pharmaphorum podcast Episode 222, Lew Bender, Intensity Therapeutics

Delving into the physics of cancer, with Lew Bender

In a new podcast, Intensity Therapeutics' Lew Bender discusses intra-tumourally injected therapeutics - a novel approach to cancer cell death.

Oncology

pharmaphorum podcast Episode 214, Marc Hedrick

On targeted radiotherapeutics, with Marc Hedrick

Dr Marc Hedrick, president and CEO of Plus Therapeutics, discusses developing targeted radiotherapeutics.

Video

Oncology

Interview at ESMO 2025 with Dr Ebrahim Delpassand

ESMO25: On radiopharmaceutical possibilities in oncology, wi...

At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix.

Oncology

Interview at ESMO 2025 with Michael Lahn, iOnctura

ESMO25: On allosteric modulation in oncology, with Michael L...

At ESMO 2025, pharmaphorum had the pleasure of speaking with Michael Lahn, Chief Medical Officer at iOnctura.

Oncology

Interview at ESMO 2025 with Sandeep Reddy, Immunity Bio

ESMO25: Harnessing the innate and the adaptive immune respon...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.

White Papers

Oncology

Life Sciences Industry Report - Part 5 feature image

Life Sciences Industry Report - Oncology

Developments in the oncology space in 2024 brought hope to both industry and patients.

Oncology

Sponsored

Patient Centricity to Integration: Enhancing Cancer Outcomes

We are living in an era of unprecedented advances in cancer treatments with transformative therapies being regularly approved.

White Papers

Sponsored

How pharma can help the post-COVID recovery of European canc...

The new Cancer Care in Europe: Recovering from COVID-19 Disruption white paper assesses the disruption to patient care and the changes physicians i

Event

Oncology

Partner Content

Tumor Models Summit

The Tumour Models Summit London returns to unite 130+ tumour modelling experts from pharma, biotech, and model providers from across the UK and Europe

Spotlight on

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content coming to you from onsite in Chicago. We’ll have features and video content rolling out as the presentations unfold day by day.

Spotlight on

ESMO 2025

Spotlight On: ESMO 2025 collates pharmaphorum's coverage of the Congress, including expert insights and interviews.

Oncology

Sponsored

How can digital and AI optimise the delivery of patient supp...

How can digital and AI optimise the delivery of patient support programs in cancer?

Oncology

Sponsored

Meeting MSL training needs in an evolving landscape

As medical treatments become more complex, the role of the Medical Science Liaison (MSL) has never been more important.

Oncology

ZS_webinar_holding_slide-approved_13.09.19

Sponsored

Cost & Management of Oncology Combination Regimens

Overview

Partner Content

Citius Oncology Signs Exclusive Commercialization Agreement ...

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

Oncology

Partner Content

Tumor Models Summit

The Tumour Models Summit London returns to unite 130+ tumour modelling experts from pharma, biotech, and model providers from across the UK and Europe

Oncology

Partner Content

3rd Cell Therapy for Autoimmune Disease Summit

Over the past year autoimmune cell therapies has seen billion-dollar investments, consistent innovation, and success stories

ESMO25: Perspective on ‘inside-out oncology’ and targeted al...

Enhertu moves into frontline breast cancer treatment

J&J claims FDA's latest national priority voucher

How blood tests can inform cancer treatment decisions, with ...

SanegeneBio raises $110m for RNAi, plus other financings

Limited prostate cancer screening backed in UK

Veraxa says delayed US listing is back on track

Targeting blood cancers with high unmet need

Enhertu moves into frontline breast cancer treatment

J&J claims FDA's latest national priority voucher

ESMO25: Perspective on ‘inside-out oncology’ and targeted al...

How blood tests can inform cancer treatment decisions, with ...

City Cancer Challenge: A gender-focused revolution in global...

Cell and gene therapies: Stagnation or maturation?

How can digital and AI optimise the delivery of patient supp...

Clinical decision-making insights for haem/oncs

Unlocking health data to improve oncology outcomes

How blood tests can inform cancer treatment decisions, with ...

Delving into the physics of cancer, with Lew Bender

On targeted radiotherapeutics, with Marc Hedrick

ESMO25: On radiopharmaceutical possibilities in oncology, wi...

ESMO25: On allosteric modulation in oncology, with Michael L...

ESMO25: Harnessing the innate and the adaptive immune respon...

Life Sciences Industry Report - Oncology

Patient Centricity to Integration: Enhancing Cancer Outcomes

How pharma can help the post-COVID recovery of European canc...

Tumor Models Summit

ASCO 2025

ESMO 2025

How can digital and AI optimise the delivery of patient supp...

Meeting MSL training needs in an evolving landscape

Cost & Management of Oncology Combination Regimens

Citius Oncology Signs Exclusive Commercialization Agreement ...

Tumor Models Summit

3rd Cell Therapy for Autoimmune Disease Summit

UK, US approve GSK's twice-yearly asthma drug

How to meet your physicians where they are online

News

Views & Analysis

Deep Dive

Editor's Picks

Webinars

Podcasts

Video

White Papers

Event

Debates & Insight

Partner Content

Editor's Picks